Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 8/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10550395 | 0.90 | FASN (0.39) | FASNESR2SHBGESR1CYP2C9 | |
| SCHEMBL10552694 | 0.86 | FASN (0.44) | FASNCYP2C9CYP3A4ALDH1A1LMNA | |
| SCHEMBL10551160 | 0.86 | FASN (0.44) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL16591212 | 0.86 | FASN (0.44) | FASNCYP2C9CYP3A4ALDH1A1LMNA | |
| SCHEMBL14313761 | 0.84 | ESR2 (0.41) | FASNESR2ESR1CYP2C9CYP3A4 | |
| SCHEMBL10550846 | 0.84 | SLC6A3 (0.43) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL10551733 | 0.84 | FASN (0.43) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL10555297 | 0.84 | FASN (0.43) | FASNCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL10550706 | 0.84 | TSHR (0.52) | FASN | |
| SCHEMBL14366247 | 0.84 | FASN (0.44) | FASNCYP2C9ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100489-B1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2024-01-10 | — | — | EP | disclosed |
| EP-3712230-B1 | LIQUID CRYSTAL COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-05-17 | — | — | EP | disclosed |
| EP-3712230-B1 | LIQUID CRYSTAL COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-05-17 | — | — | EP | disclosed |
| EP-4100489-A1 | LIQUID-CRYSTALLINE COMPOUNDS | Merck Patent GmbH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-11208595-B2 | Liquid-crystalline compounds | MERCK PATENT GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208595-B2 | Liquid-crystalline compounds | MERCK PATENT GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| WO-2021156232-A1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021156232-A1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2021-08-12 | — | — | WO | disclosed |
| US-20200299580-A1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200299580-A1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-9951277-B2 | Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| EP-3135659-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-3135659-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
| WO-2015129540-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC株式会社 | 2015-09-03 | — | — | WO | disclosed |
| US-7291367-B2 | Liquid-crystalline compounds | MERCK PATENT GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291367-B2 | Liquid-crystalline compounds | MERCK PATENT GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| EP-1482021-B1 | Pyrans as liquid crystals | MERCK PATENT GMBH (DE) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208595-B2 | Liquid-crystalline compounds | CHRM1, C1S, CHRM2 | FASN 2128/4885ESR2 1275/4885SHBG 615/4885 |
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | FASN 3041/4885ESR2 3156/4885SHBG 4379/4885 |
| US-20200299580-A1 | LIQUID-CRYSTALLINE COMPOUNDS | CHRM1, C1S, CHRM2 | FASN 2128/4885ESR2 1275/4885SHBG 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.